New drug aims to restore skin color in vitiligo patients

NCT ID NCT07223229

Recruiting now Disease control Sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new drug called EI-001 can help people with vitiligo, a condition that causes white patches on the skin. The drug works by calming the immune system to reduce inflammation. About 45 adults with nonsegmental vitiligo will receive either EI-001 or a placebo to see if it improves skin color and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SEGMENTAL VITILIGO

Contacts and locations

Show contact details

Locations

Apex Clinical Research Center, LLC (Mayfield)
RECRUITING

Mayfield Heights, Ohio, 44124, United States

Contact Email: •••••@•••••
Center for Clinical Studies
RECRUITING

Houston, Texas, 77004, United States
Linkou Chang Gung Memorial Hospital
RECRUITING

Taoyuan, Taiwan
Marvel Clinical Research
RECRUITING

Huntington Beach, California, 17742, United States
Skin Care Research, LLC
RECRUITING

Hollywood, Florida, 33021, United States
U Mass Chan Medical School
WITHDRAWN

Worcester, Massachusetts, 01605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.